Association of sodium–glucose cotransporter-2 inhibitors with mortality across the spectrum of myocardial infarction: a systematic review and meta-analysis
Abstract Background The impact of sodium–glucose cotransporter-2 (SGLT2) inhibitors on mortality following myocardial infarction (MI) remains uncertain. Additionally, the role of type 2 diabetes mellitus (T2DM) and heart failure (HF) in modulating the effectiveness of these drugs post-MI are not ful...
Saved in:
Main Authors: | Michele Maremmani, Ramin Ebrahimi, Marco Centola, Felice Achilli, Valentina Capone, Eduardo Bossone, Christian Templin, Davide Di Vece |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12933-025-02592-0 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Uninephrectomy and sodium‐glucose cotransporter 2 inhibitor administration delay the onset of hyperglycemia
by: Yuri Sakai Ishizaki, et al.
Published: (2024-11-01) -
Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
by: Yang Cao, et al.
Published: (2022-06-01) -
Sodium-glucose cotransporter-2 inhibitors increase urinary tract infections?—a cross sectional analysis of a nationwide Japanese claims database
by: Go Anan, et al.
Published: (2023-11-01) -
The first experience with sodium‐glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure
by: Anastasia D. Egorova, et al.
Published: (2022-06-01) -
Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence
by: Jian‐Yu Jhu, et al.
Published: (2025-02-01)